Search

Displaying results 5781 - 5790 of 10000 in total
  1. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  2. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.

  3. Drug

    Evixapodlin

    go.drugbank.com/drugs/DB21520
    Investigational

    Evixapodlin has a monoisotopic molecular weight of 690.22 Da. … Evixapodlin is a small molecule drug.

  4. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood

  5. Drug

    Iclaprim

    go.drugbank.com/drugs/DB06358
    Investigational

  6. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of

  7. Drug

    Spaglumic acid

    go.drugbank.com/drugs/DB08835
    Investigational

    Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid). … In eye drops, spaglumic acid is either a magnesium or sodium salt of N-Acetyl-l-aspartylglutamate. Spaglumic acid is a mast cell stabilizer.

    Synonyms: N-Acetyl-L-β-aspartyl-L-glutamic acid
  8. Drug

    Salix alba bark volatile oil

    go.drugbank.com/drugs/DB14354
    Investigational

    Salix alba bark volatile oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  9. Drug

    AT-301

    go.drugbank.com/drugs/DB16507
    Investigational

    AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine

  10. Drug

    Mitumomab

    go.drugbank.com/drugs/DB06462
    Experimental

    Mitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.